Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

Deirdre J. Cohen, Lead investigator; Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai

“Biliary tract cancer is often diagnosed at an advanced stage, and despite recent progress, there is a need for more effective first-line options that can extend survival and improve disease control”

Deirdre J. Cohen, Lead investigator; Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai

“EA2251 will explore a novel therapeutic approach in the front-line setting by evaluating ivonescimab with chemotherapy against current immunotherapy-based standards of care.”

Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics

“We are honored to collaborate with ECOG-ACRIN on EA2251 as we continue to expand the development program for ivonescimab in areas of meaningful unmet need”

Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics

“The sponsorship and conduct of this registration-enabling study by a leading cooperative oncology group underscores the scientific interest in evaluating ivonescimab in difficult-to-treat cancers, including BTC, and supports Summit’s commitment to building a robust body of clinical evidence across multiple tumor types and treatment settings.”